High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma

doi:10.12998/wjcc.v10.i3.790

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 3

This Article

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7137)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

457

WORD

197

HTML

3189

Figures (1-2)

608

Tables (1-3)

553

Sum=5004

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

510

Download

1621

Sum=2131

Jan 21, 2022 (publication date) through Mar 6, 2026

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Cohort Study

World J Clin Cases. Jan 21, 2022; 10(3): 790-801
Published online Jan 21, 2022. doi: 10.12998/wjcc.v10.i3.790

High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma

Yan-Feng Liu, Qian Chen, Xue-Zhi Liu, Jian-Ping Song

Jian-Ping Song, Department of Organ Transplantation, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong Province, China

Xue-Zhi Liu, Department of General Surgery, Shouguang People's Hospital, Shouguang 262700, Shandong Province, China

Qian Chen, Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong Province, China

Yan-Feng Liu, Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China

Author contributions: All the authors solely contributed to this paper.

Supported by Shandong Scientific and Technological Research Program, No. 2019GSF108254; and Shandong Natural Science Foundation, No. ZR2021MH339.

Institutional review board statement: Ethics approval and patient consent were waived by the MSKCC Institutional Review Board.

Informed consent statement: Informed consent from patients was waived by the MSKCC IRB per 45 CFR 46.116 and 45 CFR 164.512, since our data were retrieved from a public database.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Data sharing statement: The data that support the findings of this study are available in MSKCC (MSKCC cohort: http://www.cbioportal.org/study/summary?id=ihch_msk_2021)

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Corresponding author: Yan-Feng Liu, FRSC, MD, PhD, Doctor, Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, No. 107 Wenhua Xi Road, Jinan 250012, Shandong Province, China. liu19822012@163.com

Received: August 17, 2021
Peer-review started: August 17, 2021
First decision: November 8, 2021
Revised: November 17, 2021
Accepted: December 23, 2021
Article in press: December 23, 2021
Published online: January 21, 2022
Processing time: 151 Days and 4.2 Hours

ARTICLE HIGHLIGHTS

Research background

Intrahepatic cholangiocarcinoma (ICC) is malignancies of the biliary duct system and constitutes approximately 10%-20% of all primary liver cancers. Tumor mutation burden (TMB) is a useful biomarker across many cancer types for the identification of patients who will benefit from immunotherapy. This study collected the ICC database from the Memorial Sloan Kettering Cancer Center to investigate the impact of TMB on the prognosis of ICC patients.

Research motivation

The prognosis of ICC patients is very poor. Previous studies suggest that TMB can used to be a prognostic factor in many types of cancer. It is critical to analyze the prognostic value of TMB in ICC to help individual clinical treatment.

Research objectives

This study aims to investigate the prognostic value of TMB in patients with intrahepatic cholangiocarcinoma ICC. In particular, we sought to confirm that TMB is an independent prognostic factor of ICC and construct a nomogram model to predict the prognosis of ICC patients, which was helpful for its clinical application.

Research methods

This study is a retrospective cohort study of ICC patients. This is a study of large sample to investigate the prognostic value of TMB and other clinical characters in ICC.

Research results

TMB was an independent risk predictor for ICC. Furthermore, independent prognostic factors of ICC included CA19-9, chronic viral hepatitis, tumor resection and disease progression (metastatic disease vs solitary liver tumor). The clinical characteristics and TMB data of some cases had missing. which increased the analysis error in our study. Using a single data source also increases statistical error. Further larger–cohort studies are necessary to confirm the predictive value of TMB in the prognosis of ICC patients.

Research conclusions

These findings suggest that TMB was an independent prognostic biomarker in patients with ICC. Moreover, patients with ICC with high TMB had poor overall survival and relapse free survival as compared to those with low TMB.

Research perspectives

We will continue to collect the clinical data of ICC patients and consolidate our conclusions by expanding the present study’s sample size.